222530-34-9

Usage

Uses

Used in Pharmaceutical Industry:
BOC-1,3-CIS-ACHC-OH is used as a key intermediate in the synthesis of indazolyl-pyrimidines and related heterocycles. These compounds have been identified as potent cyclin-dependent kinase (CDK) inhibitors, which play a crucial role in regulating cell cycle progression. The inhibition of CDKs has been shown to have significant therapeutic potential in the treatment of various cancers by preventing uncontrolled cell division and proliferation.
BOC-1,3-CIS-ACHC-OH is used as a building block for the development of pharmaceuticals targeting CDKs, which can be employed in the treatment of cancer. The compound's unique structure allows for the creation of novel CDK inhibitors with improved potency, selectivity, and pharmacokinetic properties, ultimately leading to more effective cancer therapies.

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-5-8(7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t8-,9+/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 16636-51-4 (+/-)-cis-3-aminocyclohexanecarboxylic acid 
• 99-05-8 meta-aminobenzoic acid 
• 62059-56-7 cis-1,3-Cyclohexanedicarboxylic acid diethyl ester 
• 227783-03-1 (1S,3R)-Cyclohexane-1,3-dicarboxylic acid monoethyl ester 
• 121-92-6 3-nitrobenzoic acid 
• 862401-49-8 cis-3-aminocyclohexanecarboxylic acid hydrochloride 
• 218772-92-0 (±)-cis-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid 
• 218772-92-0 (±)-cis-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid 
• 334932-13-7 3-[(tert-butoxycarbonyl)amino]cyclo-hexanecarboxylic acid 
• 41235-88-5 cis-3-aminocyclohexanecarboxylic acid 

Downstream Products

• 869081-61-8 Boc-D-γ-Ach-L-^MeN-Ala-OFm 
• 712313-64-9 (1S,3R)-methyl 3-aminocyclohexanecarboxylate hydrochloride 
• 1222709-28-5 ((1S,3R)-3-aminocyclohexyl)benzylcarbamate hydrochloride 
• 202120-10-3 (1S,3R)-3-aminocyclohexylcarboxylic acid methyl ester 

Relevant academic research and scientific papers

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies.

PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF

Compounds having activity as chemotherapeutic agents are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1a, R1b, R1c, R1d, L, and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods for treating cancer (e.g., hematological cancers) are also provided.

Chemical Compounds

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

Synthesis of cyclic γ-amino acids for foldamers and peptide nanotubes

Cyclic γ-amino acids are molecular building blocks of great interest in peptide and foldamer chemistry, as they allow the preparation of new structures that are not found in Nature. In this paper, we describe the synthesis of cyclic γ-amino acids that have a cis relationship between the amino and the carboxylic acid groups. This arrangement, in most cases, induces the resulting peptides to adopt a flat conformation, which makes them appropriate for the design of foldamers that adopt β-sheet-type structures. We describe the synthesis of cyclic γ-amino acids that have a cis relationship between the amino and the carboxylic acid groups. This makes them suitable for the design of foldamers that adopt β-sheet-type structures.

Self-assembled peptide tubelets with 7 A pores

Here we report the preparation and structural characteristics of self-assembling peptide tubelets composed of 32-membered rings formed of alternating cx-amino acids and cis-3-aminocyclohexanecarboxylic acids. The tubelets possess a partial hydrophobic cor

Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on the benzothiazole structure

Two parallel synthetic methods using solid-supported reagents were established to examine the rapid optimization of weak hit compound 1. Several compounds showed high potency in the low nanomolar range against N-myristoyltransferase. The structure-activity relationship (SAR) and antifungal activities of a series of novel 2-aminobenzothiazole N-myristoyltransferase inhibitors are presented.